Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.
about
Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery SystemsInhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.Pharmaceutical particle engineering via spray drying.Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment.Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers.Respirable low-density microparticles formed in situ from aerosolized brittle matrices.Swellable ciprofloxacin-loaded nano-in-micro hydrogel particles for local lung drug deliveryCharacterizations of particle size distribution of the droplets exhaled by sneeze.Delivery of antibiotics to the respiratory tract: an update.Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?Dry powder inhalation: past, present and future.Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?Physicochemical characteristics and bronchial epithelial cell cytotoxicity of Folpan 80 WG(R) and Myco 500(R), two commercial forms of folpet.Formulation of inhalable lipid-based salbutamol sulfate microparticles by spray drying technique.The impact of particle preparation methods and polymorphic stability of lipid excipients on protein distribution in microparticles.Appropriate selection of an aggregation inhibitor of fine particles used for inhalation prepared by emulsion solvent diffusion.Phospholipids in pulmonary drug delivery
P2860
Q28076594-1A50ACF9-3A8C-4D0B-A8A1-6D515FE9F5ADQ28077482-606817C8-AA94-4348-AD59-0EB00AE38AD0Q30496354-2A85CC36-7143-4DB1-99AA-000CDA4BD1B4Q33758340-E64BB02B-2EAC-4A7B-9EA4-3939CD0DE124Q34496228-447D7580-A0FC-4AD3-842A-0682277DF06AQ34508257-4875A089-FC6D-48E1-9049-2462D6005C1DQ34577434-D3914D2E-9FCD-45DE-B72C-7057953A395BQ34985411-5FE2038B-9263-425F-9278-95D811551973Q37564542-470D5BD2-DF35-4086-8F16-96A6EF42E0C8Q38340865-F3881BEF-C6EA-47CC-B3D5-96F7DED4631CQ38830375-C985EE7D-76A4-4AF6-94BA-7BED0BEA9D5BQ39031123-53CC18FE-7C59-40E7-A356-052C222922F0Q39814345-36B2D89A-0B59-468A-AAF9-B72D2072308FQ42168488-DA4CAB38-42C0-4F02-8CAF-740E7A4F3341Q47951851-32BDB851-F294-4DE1-8744-F83B1D508A11Q51293398-34A60771-ADD6-486D-A334-C11D5D9AE20EQ59089495-4DD5097B-3320-4342-9219-70A7F221C991
P2860
Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Formulation and characterizati ...... les for dry powder inhalation.
@ast
Formulation and characterizati ...... les for dry powder inhalation.
@en
type
label
Formulation and characterizati ...... les for dry powder inhalation.
@ast
Formulation and characterizati ...... les for dry powder inhalation.
@en
prefLabel
Formulation and characterizati ...... les for dry powder inhalation.
@ast
Formulation and characterizati ...... les for dry powder inhalation.
@en
P2093
P1476
Formulation and characterizati ...... les for dry powder inhalation.
@en
P2093
Gabrielle Pilcer
Karim Amighi
Thami Sebti
P304
P356
10.1007/S11095-006-9789-4
P577
2006-05-02T00:00:00Z